Save

P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants

PHASE1RECRUITING

A Phase 1, Open-Label, Drug-drug Interaction, and Randomized, Double-blind, Controlled, Multiple-dose Pharmacokinetics and Safety Study of Xeruborbactam Oral Prodrug (QPX7831) in Combination with Ceftibuten in Healthy Adult Participants.

Simpliy with AI

Study details:

Qpex Biopharma, Inc. is developing an oral dosage form that delivers Xeruborbactam, a new boron-based beta-lactamase inhibitor with activity against both serine and metallo-beta-lactamases, for oral treatment in combination with a beta-lactam antibiotic. Ceftibuten is a cephalosporin antibiotic approved in the US for acute exacerbations of chronic bronchitis, acute bacterial otitis media and pharyngitis/tonsillitis.

This Phase 1 study will assess if a PK interaction exists between xeruborbactam oral prodrug and ceftibuten when given in combination at doses of each drug that have previously been shown to be safe. The study will also assess the safety of the combination with dosing over 10 days. Study Objectives:.

1. To assess the safety, tolerability, and PK of single and multiple doses of xeruborbactam oral prodrug and ceftibuten both in combination and alone, in healthy adult participants. 2.

To assess whether there is any PK interaction between xeruborbactam oral prodrug and ceftibuten when administered in combination to healthy adult participants.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Participant must be a healthy adult male or female, 18 to 55 years of age (inclusive) at the time of screening.

Participants who are overtly medically healthy with clinically insignificant screening results (eg, laboratory profiles, medical histories, ECGs, physical examination) as assessed by the investigator, sub-investigator, or medical officer.

Body mass index (BMI) ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive). Note: BMI = kg/m2 where kg is a weight in kilograms and m2 is a height in meters squared.

Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

If male, agree to be sexually abstinent or agree to use 2 approved methods of contraception when engaging in sexual activity from study check-in through 30 days following the last administration of the study drug, and to not donate sperm during this same period of time. If the sexual partner is surgically sterile, contraception is not necessary.

Females of childbearing potential must either be sexually abstinent for 14 days prior to Day 1 and agree to remain so through 30 days following the last administration of the study drug, OR have been using (or agree to use) 2 of the following acceptable methods of birth control for the times specified: 1. Intra-uterine device (IUD) in place for at least 3 months prior to Day 1 through 30 days following the final dosing of the study drug 2. Barrier method (condom or diaphragm) for at least 14 days prior to Day 1 through 30 days following the final dosing of the study drug 3. Stable hormonal contraceptive for at least 3 months prior to Day 1 and barrier method (condom or diaphragm) for at least 14 days prior to Day 1 through 30 days following final dosing of the study drug 4. Surgical sterilization (vasectomy) of partner at least 6 months prior to Day 1.

Capable of giving signed informed consent as described in Appendix 1 Informed Consent Form (Section 10.1.3) that includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.

Documented hypersensitivity reaction or anaphylaxis to any medication, including ceftibuten or other beta-lactam antibiotics (e.g. cephalosporins, penicillins, carbapenems or monobactams) or any excipients used in this formulation.

Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).

Females who are pregnant or lactating.

Surgery within the past 3 months prior to Day 1 determined by the investigator, sub-investigator, or medical officer to be clinically relevant.

Any acute illness within 30 days prior to Day 1.

Any other condition or prior therapy, which, in the opinion of the investigator, sub-investigator, or medical officer would make the participant unsuitable for this study.

Use of any prescription medication (with the exception of hormonal contraceptives or hormone replacement therapy for females) within 14 days prior to Day 1.

Use of any over-the-counter medication, including herbal products, probiotics and vitamins, within the 7 days prior to Day 1. Up to 2 grams per day of paracetamol is allowed for acute events at the discretion of the investigator, sub-investigator, or medical officer.

Use of antacids, H2 receptor blockers or proton pump inhibitors 7 days prior to Day 1. This includes calcium carbonate.

Participation in another investigational clinical trial within 30 days prior to Day 1 or within 5 half-lives of the previous investigational drug, whichever is longer.

QTc corrected according to Fridericia's formula (QTcF) interval > 450 msec for males and > 470 for females or history of prolonged QT syndrome at screening or check-in (Day -1).

Calculated creatinine clearance < 80 mL/min (Cockcroft-Gault method) at screening or check-in (Day -1).

Any clinically significant abnormalities in laboratory values at screening or check-in (Day -1), in particular: 1. White blood cell count < 3,000/mm3, hemoglobin < 11g/dL 2. Absolute neutrophil count < 1,200/mm3 or platelet count < 120,000/mm3 3. Liver function abnormalities at screening or check-in (Day -1) (defined by an elevation in bilirubin, AST, or ALT > ULN for participants based on age and sex)

Blood donation or significant blood loss (ie, > 500 mL) within 56 days prior to Day 1.

Plasma donation within 7 days prior to Day 1.

Positive urine drug/alcohol testing at screening or check-in (Day -1).

History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.

Use of more than 5 packs/week of cigarettes (or equivalent amount of nicotine-containing product) within 6 months prior to Day 1. Use of all nicotine containing products 48 hours prior to admission to clinical research unit. Participants must agree to refrain from smoking for the duration of the study.

Excessive intake of alcohol, defined as an average daily intake of > 2 standard drinks for women and > 4 standard drinks for men, (standard drink is the equivalent to 4 oz of wine (approximately 12% abv), 12 oz of regular beer (approximately 5% abv), or 1.5 oz of spirits (80 proof).

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : Yes

Gender eligible for study: All

Things to know

Study dates

Study start: 2024-01-30

Primary completion: 2024-09-12

Study completion finish: 2024-12-07

Study type

TREATMENT

Phase

PHASE1

Trial ID

NCT06079775

Intervention or treatment

DRUG: Xeruborbactam Oral Prodrug

DRUG: Ceftibuten

DRUG: Xeruborbactam Oral Prodrug Placebo

DRUG: Ceftibuten Placebo

Conditions

• Bacterial Infections

Condition: Bacterial Infections
DRUG: Xeruborbactam Oral Prodrug and other drugs
Adelaide, South Australia, Australia
Sponsor: Qpex Biopharma, Inc.

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

CMAX

Research sites nearby

Select from list below to view details:

CMAX
Adelaide, South Australia, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Single Dose Drug-Drug-Interaction Crossover & Multiple Dose Cohorts During the DDI crossover part of the study, 24 subjects will be enrolled into 3 cohorts of 8 subjects each, Cohorts 1, 2, \& 3 respectively. All subjects in Cohorts 1, 2, and 3 will receive a single dose of xeruborbactam oral prodrug on Day 1. On Day 6, they will receive a single dose of ceftibuten. On Day 9 they will receive a single combined dose of xeruborbactam oral prodrug and ceftibuten. During the MAD part of the study, 48 subjects will be enrolled into 3 cohorts of 16 subjects each, Cohorts 4, 5, \& 6 respectively. All subjects in Cohorts 4, 5, and 6 will receive either a combined dose of xeruborbactam oral prodrug and ceftibuten, active ceftibuten, or active xeruborbactam oral prodrug. Cohort 4 \& 5 will be dosed BID on Days 1 through 9, with last and final dose on the morning of Day 10. Cohort 6 will be dosed BID on Day 1, and then QD on Days 2 through 10 with last dose on the morning of Day 10. All subjects will be followed for safety and PK data collection.	DRUG: Xeruborbactam Oral Prodrug Experimental
PLACEBO_COMPARATOR: Placebo Comparator to maintain the blind During the multiple-dose portion of the study, Xeruborbactam Oral Prodrug Placebo and Ceftibuten placebo will be used to maintain the blind. In Cohorts 4, 5, and 6, ten (10) subjects in each cohort will receive a combined dose of xeruborbactam oral prodrug and ceftibuten. Three (3) subjects in each cohort will receive active ceftibuten capsules with xeruborbactam oral prodrug placebo capsules. Three (3) subjects in each cohort will receive active xeruborbactam oral prodrug capsules with ceftibuten placebo capsules.	DRUG: Xeruborbactam Oral Prodrug Placebo Placebo Comparator

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: Single Dose Drug-Drug-Interaction Crossover & Multiple Dose Cohorts

During the DDI crossover part of the study, 24 subjects will be enrolled into 3 cohorts of 8 subjects each, Cohorts 1, 2, \& 3 respectively.
All subjects in Cohorts 1, 2, and 3 will receive a single dose of xeruborbactam oral prodrug on Day 1. On Day 6, they will receive a single dose of ceftibuten. On Day 9 they will receive a single combined dose of xeruborbactam oral prodrug and ceftibuten.
During the MAD part of the study, 48 subjects will be enrolled into 3 cohorts of 16 subjects each, Cohorts 4, 5, \& 6 respectively.
All subjects in Cohorts 4, 5, and 6 will receive either a combined dose of xeruborbactam oral prodrug and ceftibuten, active ceftibuten, or active xeruborbactam oral prodrug.
Cohort 4 \& 5 will be dosed BID on Days 1 through 9, with last and final dose on the morning of Day 10.
Cohort 6 will be dosed BID on Day 1, and then QD on Days 2 through 10 with last dose on the morning of Day 10.
All subjects will be followed for safety and PK data collection.

DRUG: Xeruborbactam Oral Prodrug

Experimental

PLACEBO_COMPARATOR: Placebo Comparator to maintain the blind

During the multiple-dose portion of the study, Xeruborbactam Oral Prodrug Placebo and Ceftibuten placebo will be used to maintain the blind. In Cohorts 4, 5, and 6, ten (10) subjects in each cohort will receive a combined dose of xeruborbactam oral prodrug and ceftibuten. Three (3) subjects in each cohort will receive active ceftibuten capsules with xeruborbactam oral prodrug placebo capsules. Three (3) subjects in each cohort will receive active xeruborbactam oral prodrug capsules with ceftibuten placebo capsules.

DRUG: Xeruborbactam Oral Prodrug Placebo

Placebo Comparator

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Incidence of Treatment -Emergent Adverse events by subject and by cohort (single dose, multiple doses)	Number of patients with Treatment-Emergent Adverse Events by subject, by cohort, severity and relationship to treatment	16 days
Number of patients with changes from baseline in safety parameters	Number of patients with changes in safety parameters before and after dosing by subject and cohort	16 days
Peak plasma Concentration measurements by subject and by cohort (Cmax)	Comparison will be performed between the cohorts for concentration measurements (Cmax). Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed.	16 days
Time concentration data measurements by subject and by cohort (Tmax)	Comparison will be performed between the cohorts for time concentration data measurements (Tmax)	16 days
Area under the plasma concentration versus time curve (AUC) between cohorts	Comparison will be performed between the cohorts for area under the plasma concentration versus time curve (AUC). Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed.	16 days
Urine Pharmacokinetic (PK) amount excreted by subject and by cohort	Urine Pharmacokinetic (PK) parameters such as amount excreted will be calculated from urinary excretion data	16 days
Urine Pharmacokinetic (PK) % dose excreted by subject and by cohort	Urine Pharmacokinetic (PK) parameters such as amount of % dose excreted will be calculated from urinary excretion data	16 days

Secondary outcome

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants